Dose adjustment of carboplatin in patients on hemodialysis

Medical Oncology

Volumn 31, Issue 3, 2014, Pages

  Guddati, Achuta K ^a   Joy, Parijat S ^b   Marak, Creticus P ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c Tahlequah City Hospital   (United States)

Author keywords

AUC; Carboplatin; Dose; Hemodialysis

Indexed keywords

CARBOPLATIN; PROTEIN; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG INFUSION; DRUG OVERDOSE; DRUG SAFETY; END STAGE RENAL DISEASE; FACTORIAL ANALYSIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; PROGNOSIS; RENAL REPLACEMENT THERAPY;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS;

EID: 84892613144     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0848-0     Document Type: Article

References (28)

1. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93-9.
2. Fischereder M, Jauch KW. Prevalence of cancer history prior to renal transplantation. Transpl Int. 2005;18(7):779-84. doi: 10.1111/j.1432-2277.2005. 00109.x.
3. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84. doi: 10.1002/cncr.22904.
4. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21(7):1395-403. doi: 10.1093/annonc/mdp598.
5. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115-24. doi: 10.1097/MAJ.0b013e31812dfe1e.
6. Boisdron-Celle M, Lebouil A, Allain P, Gamelin E. Pharmacokinetic properties of platinium derivatives. Bull Cancer. 2001;88 Spec No:S14-9.
7. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1- cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984;44(11):5432-8.
8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-56.
9. Mazumdar M, Smith A, Tong WP, Motzer RJ. Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting. J Natl Cancer Inst. 2000;92(17):1434-6.
10. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87(8):573-80.
11. Newell DR, Pearson AD, Balmanno K, Price L, Wyllie RA, Keir M, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol. 1993;11(12):2314-23.
12. Ishibashi T, Yano Y, Oguma T. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol. 2002;50(3):230-6. doi: 10.1007/s00280-002-0488-5.
13. Sato S, Fujiwara H, Oishi T, Shimada M, Machida S, Takei Y, et al. Evaluation of a formula for individual dosage of nedaplatin based on renal function. Cancer Chemother Pharmacol. 2012;69(3):599-603. doi: 10.1007/s00280-011-1739-0.
14. Inoue A, Saijo Y, Kikuchi T, Gomi K, Suzuki T, Maemondo M, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol. 2004;15(1):51-4.
15. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007;17(4):739-63. doi: 10.1111/j.1525-1438.2007.00847.x.
16. Suzuki S, Koide M, Sakamoto S, Matsuo T. Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. Nephrol Dial Transpl. 1997;12(1):137-40.
17. Heijns JB, van der Burg ME, van Gelder T, Fieren MW, de Bruijn P, van der Gaast A, et al. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Cancer Chemother Pharmacol. 2008;62(5):841-7. doi: 10.1007/s00280-007-0671-9.
18. Yoshida H, Sumi T, Abe K, Ishiko O. Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer. Eur J Gynaecol Oncol. 2009;30(5):583-5.
19. Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron. 1994;66(2):157-61.
20. Gouyette A, Lemoine R, Adhemar JP, Kleinknecht D, Man NK, Droz JP, et al. Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. Cancer Treat Rep. 1981;65(7-8):665-8.
21. Hofmann G, Bauernhofer T, Krippl P, Lang-Loidolt D, Horn S, Goessler W, et al. Plasmapheresis reverses all side-effects of a cisplatin overdose-a case report and treatment recommendation. BMC Cancer. 2006;6:1. doi: 10.1186/1471-2407-6-1.
22. Motzer RJ, Niedzwiecki D, Isaacs M, Menendez-Botet C, Tong WP, Flombaum C, et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol. 1990;27(3):234-8.
23. Takezawa K, Okamoto I, Fukuoka M, Nakagawa K. Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J Thorac Oncol. 2008;3(9):1073-5. doi: 10.1097/JTO. 0b013e318183af89.
24. Fong MK, Fetterly GJ Jr, McDougald LJ, Iyer RV. Carboplatin pharmacokinetics in a patient receiving hemodialysis. Pharmacotherapy. 2013. doi: 10.1002/phar.1354.
25. Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, et al. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol. 2010;66(4):813-7. doi: 10.1007/s00280-010-1366-1.
26. Kodama J, Sasaki A, Masahiro S, Seki N, Kusumoto T, Nakamura K, et al. Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. Oncology Lett. 2010;1(3):511-3. doi: 10.3892/ol-00000090.
27. Watanabe M, Aoki Y, Tomita M, Sato T, Takaki Y, Kato N, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol. 2002;84(2):335-8. doi: 10.1006/gyno.2001.6527.
28. Hiraike M, Hiraki Y, Misumi N, Hanada K, Tsuji Y, Kamimura H, et al. Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemother Pharmacol. 2012;69(3):845-8. doi: 10.1007/s00280-011- 1802-x.